

## Measles Virus, MVs/Utah.USA/6.17 [H1]

Catalog No. NR-52253

For research use only. Not for use in humans.

### Contributor:

Bettina Bankamp, Ph.D., Division of Viral Diseases, Viral Vaccine Preventable Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

### Manufacturer:

BEI Resources

### Product Description:

Virus Classification: *Paramyxoviridae, Morbillivirus*

Species: Measles virus

Strain/Isolate: MVs/Utah.USA/6.17 [H1]

Genotype: H1

Original Source: Measles virus (MeV), MVs/Utah.USA/6.17 [H1] was collected from a nasopharyngeal swab in February 2017 in Utah, USA, and isolated on May 8, 2018.<sup>1</sup>

Comments: MeV, MVs/Utah.USA/6.17 [H1] belongs to genotype H1 and the sequence of the nucleoprotein gene is available (GenBank: [MN602401](https://www.ncbi.nlm.nih.gov/nuclot/MN602401)).

MeV is a single-strand negative sense non-segmented RNA virus.<sup>2</sup> MeVs are divided into 8 clades, designated A through H, with 24 genotypes based on the sequences of the hemagglutinin (HA) and nucleoprotein (N) genes. The sequence of the 450 nucleotides that encode the carboxyl-terminal 150 amino acids of the nucleoprotein (N-450) is needed to determine the genotype.<sup>2,3</sup> In 2018, four new genotypes were identified: B3, D4, D8 and H1. In 2000, measles was declared eliminated in the US by the WHO, but in 2019 the highest numbers of cases and outbreaks were reported.<sup>4</sup>

### Material Provided:

Each vial contains approximately 1.0 mL of cell lysate and supernatant from *Cercopithecus aethiops* kidney epithelial cells with human signaling lymphocytic activation molecule (Vero E6-hSLAM) infected with MeV, MVs/Utah.USA/6.17 [H1].

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

### Packaging/Storage:

NR-52253 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

### Growth Conditions:

Host: *Cercopithecus aethiops* kidney epithelial cells with human signaling lymphocytic activation molecule (Vero E6-hSLAM)

Growth Medium: Dulbecco's Modified Eagle's Medium containing Earle's Balanced Salt Solution, non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate and 1500 mg per L of sodium bicarbonate supplemented with 2% fetal bovine serum, or equivalent

Infection: Cells should be 70% to 90% confluent

Incubation: 2 to 4 days at 37°C and 5% CO<sub>2</sub>

Cytopathic Effect: Syncytia formation

### Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Measles Virus, MVs/Utah.USA/6.17 [H1], NR-52253."

### Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see [www.cdc.gov/biosafety/publications/bmb15/index.htm](http://www.cdc.gov/biosafety/publications/bmb15/index.htm).

### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

### Use Restrictions:

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Bankamp, B., Personal Communication.
2. Coughlin, M. M., et al. "Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies." *Viruses* 9 (2017). doi: 10.3390/v9010011. PubMed: 28106841.
3. Magana, L. C., et al. "Complete Genome Sequences of Mumps and Measles Virus Isolates from Three States in the United States." *Genome Announc.* 33 (2017). doi: 10.1128/genomeA.00748-17. PubMed: 28818890.
4. Patel, M., et al. "National Update on Measles Cases and Outbreaks – United States, January 1 – October 1, 2019." *MMWR* 40 (2019): 893-896. PubMed: 31600181.

ATCC® is a trademark of the American Type Culture Collection.

